

**Amendments to the Claims**

Claim 1 (Cancelled).

Claim 2 (Currently Amended): A method of screening for an endometrial cancer in a subject comprising:

(a) detecting the level or amount of human chaperonin 10 in a biological sample obtained from the subject, wherein the human chaperonin 10 ~~is the native-~~  
~~sequence polypeptide of human chaperonin 10 or a fragment, precursor, modified form,~~  
~~chimeric form, complex, or derivative thereof~~ has an amino acid sequence as set forth in  
SEQ ID NO:1 or an amino acid sequence having at least 90% sequence identity to the  
sequence set forth in SEQ ID NO:1, and wherein the biological sample is ~~blood or an~~  
endometrial tissue ~~extract sample~~; and

(b) comparing the level or amount in step (a) with a level or amount of human chaperonin 10 in a control,  
wherein ~~a significant difference in the~~ an elevated or increased level or amount of human chaperonin 10 in the biological sample, relative to the corresponding level or amount in the control, is indicative of endometrial cancer.

Claim 3 (Currently Amended): The method of claim 2, ~~further comprising wherein~~  
step (a) comprises:

~~(a)~~ (i) contacting the biological sample obtained from the subject with at least one binding agent that specifically binds to human chaperonin 10; and,

~~(b)~~ (ii) detecting in the biological sample the level or amount of human chaperonin 10 that binds to the binding agent; and

~~— (c) —~~ comparing the level or the amount of bound human chaperonin 10 with the  
level or amount in a control;

~~—wherein a significant difference in the level or amount of bound human chaperonin 10 in the biological sample, relative to the corresponding level or amount in the control, is indicative of endometrial cancer.~~

Claim 4 (Previously Presented): The method of claim 3, wherein the binding agent is an antibody.

Claim 5 (Cancelled).

Claim 6 (Currently Amended): The method of claim 3, wherein ~~the~~ a level or amount of human chaperonin 10 in the biological sample that is significantly higher than the level or amount of human chaperonin 10 in the control, ~~and~~ is indicative of endometrial cancer.

Claims 7-8 (Cancelled).

Claim 9 (Currently Amended): The method of claim 2, wherein the endometrial tissue ~~extract~~ sample is obtained from an endometrial tumor.

Claims 10-18 (Cancelled).

Claim 19 (Currently Amended): A method for monitoring the progression of endometrial cancer in a subject comprising:

(a) detecting in a biological sample obtained from the subject, at a first time point, a level or amount of human chaperonin 10, wherein the biological sample is ~~blood or an endometrial tissue extract~~ sample, and wherein the human chaperonin 10 ~~is the native sequence polypeptide of human chaperonin 10 or a fragment, precursor, modified form, chimeric form, complex, or derivative thereof~~ has an amino acid sequence as set

forth in SEQ ID NO:1 or an amino acid sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO:1;

- (b) repeating step (a) at a subsequent point in time; and
- (c) comparing the levels or amounts of human chaperonin 10 detected in steps (a) and (b), ~~and thereby monitoring the~~ wherein an elevated or increased level or amount of human chaperonin 10 from step (b) relative to the level or amount of human chaperonin 10 from step (a) indicates a progression of endometrial cancer.

Claims 20-49 (Cancelled).

Claim 50 (New): The method of claim 19, wherein a level or amount of human chaperonin 10 in the biological sample of step (a) that is significantly higher than the level or amount of human chaperonin 10 in the biological sample of step (b) is indicative of endometrial cancer.

Claim 51 (New): The method of claim 19, wherein step (a) comprises:

- (i) contacting the biological sample obtained from the subject with at least one binding agent that specifically binds to human chaperonin 10; and,
- (ii) detecting in the biological sample the level or amount of human chaperonin 10 that binds to the binding agent.

Claim 52 (New): The method of claim 51, wherein the binding agent is an antibody.

Claim 53 (New): The method of claim 2, wherein the detection of human chaperonin 10 is conducted using mass spectrometry.

Claim 54 (New): The method of claim 19, wherein the detection of human chaperonin 10 is conducted using mass spectrometry.